Pyroxamide|cas 382180-17-8|DC Chemicals

Cas No.:	382180-17-8
Chemical Name:	Pyroxamide
Synonyms:	Pyroxamide;N-Hydroxy-N'-3-pyridinyloctanediamide;N1-Hydroxy-N8-(pyridin-3-yl)octanediamide;N'-hydroxy-N-pyridin-3-yloctanediamide;PYROXAMIDE(NSC 696085);N1-Hydroxy-N8-3-pyridinyl-octanediamide;NCI60_034337;AS-19542;12N86DSS23;Pyroxamide, >=97% (HPLC);NSC696085;Octanediamide, N-hydroxy-N'-3-pyridinyl-;NSC-696085;SCHEMBL154681;N1-hydroxy-N8-(pyridin-3-yl)octanediamide;BCPP000095;BDBM50473982;A25478;Octanedioic acid hydroxyamide pyridin-3-ylamide;HB1395;MFCD13194970;N-Hydroxy-N'-3-pyridinyloctanediamid e;NSC 696085;POLAR HYBRID COMPOUND;suberoyl-3-aminopyridineamide hydroxamic acid;Q27165709;HY-13216;BCP02301;DB12847;BRD-K11663430-001-01-5;EX-A085;382180-17-8;AC-36015;CHEBI:93953;MLS006010135;N1-hydroxy-N8-3-pyridinyloctanediamide;A1-01901;C13H19N3O3;UNII-12N86DSS23;SMR004701260;DTXSID70191595;NCGC00346891-01;pyroxamide;CS-0003180;CHEMBL353581;AKOS015899763;FT-0734893;N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide;NS00069328
SMILES:	O=C(NO)CCCCCCC(NC1=CC=CN=C1)=O
Formula:	C₁₃H₁₉N₃O₃
M.Wt:	265.30826
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.For the detailed information of Pyroxamide, the solubility of Pyroxamide in water, the solubility of Pyroxamide in DMSO, the solubility of Pyroxamide in PBS buffer, the animal experiment (test) of Pyroxamide, the cell expriment (test) of Pyroxamide, the in vivo, in vitro and clinical trial test of Pyroxamide, the EC50, IC50,and Affinity of Pyroxamide, Please contact DC Chemicals.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC73305	TYA-018	TYA-018 (TYA018) is a potent, isoform-selective inhibitor of HDAC6 with IC50 of 10 nM, inhibits tubulin acetylation (Ac-Tubulin) with EC50 of 120 nM in cell-based assay in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs).
DC70854	Tucidinostat	Tucidinostat (Chidamide, HBI-8000, CS055) is a novel histone deacetylase (HDAC) inhibitor with IC50 of 95/160/67/733/78/432 nM for HDAC1/2/3/8/10/11, respectively; shows no activity against Class IIa HDAC4/4/7/9 and HDAC6; demonstrates significant and broad spectrum in vitro and in vivo antitumor activity, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.
DC70821	T-518	T-518 (T518) is a potent, highly selective, brain penetrant, oral HDAC6 inhibitor with IC50 of 36 nM.T-518 did not obviously inhibit human HDAC1, 4, or 7 at 10 uM, which belongs to Class I or Class IIa HDAC.T-518 showed brain penetration in an oral dose and blocked HDAC6-dependent tubulin deacetylation at Lys40 in mouse hippocampus.T-518 decreased RIPA-insoluble tau accumulation (3-month treatment, 1 and 3 mg/kg), restored impaired axonal transport and novel object recognition in the P301S tau Tg mouse (tauopathy model) by 2-week treatment with dose 1 and 3 mg/kg.
DC70534	KA2507	KA2507 (KA-2507, KA 2507) is a potent and selective inhibitor of HDAC6 with IC50 of 2.5 nM, >300-fold selectivity over other HDACs.KA2507 demonstrated cellular potency (IC50=150 nM) in a cellular assay measuring induction of acetylated α-tubulin, a marker of HDAC6 inhibition.KA2507 displays antiproliferative effects against a set of 93 human cancer cells with IC50 of 2-30 uM.KA2507 inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model.
DC70478	HDAC3 inhibitor PT3	HDAC3 inhibitor PT3 is a novel potent, selective, BBB-permeable HDAC3 inhibitor.PT3 exhibited higher selectivity for HDAC3 over HDAC1, HDAC6, and HDAC8 compared to the reference compound CI994.PT3 upregulated H3K9 acetylation, CREB 1, BDNF, TRKB, Nr4a2, c-fos, PKA, GAP 43 and MMP9 expression in mouse neuronal (N2A) cells.PT3 significantly improved the discrimination index in C57/BL6 mice in the novel object recognition (NOR) model, significant increased in H3K9 acetylation in hippocampus.PT3 upregulated CREB 1, BDNF, TRKB, Nr4a2, c-fos, PKA, GAP 43, PSD 95 and MMP9 expression in mice treated with PT3.
DC70420	FT234	FT234 (FT-234) is a selective HDAC11 inhibitor.FT234 demonstrated significant reduction in self-renewal stem-like SP cells with 2 uM FT234 or FT895, as well as the formation of vascular networks by SP cells at 5 uM compound treatment.FT234 significantly decreased the mRNA of Sox2 as well as its target genes like HK2 and PDK2 in SPAdh cells.FT234 compound inhibited the growth and viability by 60–80% in both A549 and H1650 cells at 5-10 uM, inhibited the viability of cancer cell lines A549 and H1650 ranged from 4.663–6.594 uM, reduced the viability of chemo-resistant cancer cells as well as chemo-insensitive CSCs.FT234 selectively prevent growth of cancer cells in presence of cancer associated fibroblasts (CAFs).
DC70098	KT-531	KT-531 (KT531) is a potent, selective HDAC6 inhibitor with IC50 of 8.5 nM, displays 39-fold selectivity.
DC49583	Elevenostat	Elevenostat (JB3-22) is a selective HDAC11 inhibitor (IC50=0.235 µM). Anti-multiple myeloma (MM) activity.
DC7673	Splitomicin	Splitomicin is a derivative of β-naphthol is an inhibitor of Silent Information Regulator 2 (SIR2).
DC11014	SALL4 peptide FFW	SALL4 peptide FFW (RRKFAKFQWI, FFW peptide) is a potent therapeutic SALL4 peptide antagonist of SALL4-NURD (nucleosome remodeling deacetylase) interaction with target affinity of 23 nM.